The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
% SDS-PAGE. Prepared from the supernatant of activated platelets by heparin-agarose affinity chromatography and gel filtration.
Protein of human blood/plasma origin. The starting material was tested prior to initiation of the manufacturing process, and was found negative or nonreactive for anti-HIV-1/2, HIV-1 antigen(s), HBsAg, STS, anti- HCV, anti-HBcore and anti-HTLV I & II.
Extinction coefficient: E (1 %; 1 c m, 280 nm) = 2.6 (calculated based upon amino acid sequence and molecular weight).
Concentration information loading...
Shipped on dry ice. Upon delivery aliquot and store at -80ºC. Avoid freeze / thaw cycles.
Pro platelet basic protein (chemokine (C-X-C motif) ligand 7)
Small inducible cytokine subfamily B member 7
Small-inducible cytokine B7
LA-PF4 stimulates DNA synthesis, mitosis, glycolysis, intracellular cAMP accumulation, prostaglandin E2 secretion, and synthesis of hyaluronic acid and sulfated glycosaminoglycan. It also stimulates the formation and secretion of plasminogen activator by human synovial cells. NAP-2 is a ligand for CXCR1 and CXCR2, and NAP-2, NAP-2(73), NAP-2(74), NAP-2(1-66), and most potent NAP-2(1-63) are chemoattractants and activators for neutrophils. TC-1 and TC-2 are antibacterial proteins, in vitro released from activated platelet alpha-granules. CTAP-III(1-81) is more potent than CTAP-III desensitize chemokine-induced neutrophil activation.
Belongs to the intercrine alpha (chemokine CxC) family.
Proteolytic removal of residues 1-9 produces the active peptide connective tissue-activating peptide III (CTAP-III) (low-affinity platelet factor IV (LA-PF4)). Proteolytic removal of residues 1-13 produces the active peptide beta-thromboglobulin, which is released from platelets along with platelet factor 4 and platelet-derived growth factor. NAP-2(1-66) is produced by proteolytical processing, probably after secretion by leukocytes other than neutrophils. NAP-2(73) and NAP-2(74) seem not be produced by proteolytical processing of secreted precursors but are released in an active form from platelets.